Alector Pipeline Webinar: Advancing Next Generation Medicines for Neurodegeneration - ALECTOR INC

Financial Performance:

• No specific financial results (revenue, earnings, cash flow) for the current quarter were disclosed as this was a scientific update webinar rather than a quarterly earnings release.
• A licensing agreement with Genentech-Rosch (BioTherate) for the GKs enzyme program provided significant financial runway extension and validation, allowing the company to fund multiple drug candidates into the clinic.
• The runway is extended to 2029, supported by the Genentech partnership proceeds, enabling the advancement of at least three programs (AL-137, AL-164, AL-062) without immediate dilution or new external financing requirements.
• Management highlighted a "low cost of goods" manufacturing process as a competitive advantage, particularly for AL-137.

Guidance and Future Outlook:

• AL-137 (Anti-Aβ Antibody): First-in-human (Phase 1a) in healthy volunteers scheduled to commence in Australia by April 2025, targeting end of Q2/early Q3 2027 for a comprehensive safety and exposure dataset. Phase 1b (patients) in the U.S. and Australia planned for late 2027, with efficacy data (PET/biomarkers) expected by Q4 2028.
• AL-164 (Anti-Tau siRNA) & AL-062 (Anti-α-Synuclein siRNA): CMC work initiated; First-in-Human (Phase 1) trials in patients targeted for Q2 2028 with subcutaneous administration.
• Long-term Goals: Aiming to remove >90% of Aβ plaques within 3–6 months for AL-137; targeting ≥50% knockdown for tau and alpha-synuclein therapeutics.
• Strategic Outlook: Continued focus on large neurodegenerative indications (Alzheimer's, Parkinson's, Lewy Body Dementia) while acknowledging potential exploration of rare diseases like PSP; intent to advance three core programs internally with the possibility of future partnerships.

Business Segments and Product Lines:

• AL-137 (Brain-enabled Anti-Aβ Antibody): A bispecific antibody targeting the pyroglutamate 3 (pGlu3) Aβ epitope with full IgG1 effector function and a unique TFR-binding domain. Designed for subcutaneous (SC) administration to minimize anemia and infusion reaction risks compared to IV competitors like lecanemab and donanemab.
• AL-164 (Brain-enabled Anti-Tau siRNA): An antibody-oligoconjugate (AOC) delivering siRNA into neurons to reduce tau production. Demonstrated homogeneous brain uptake in non-human primates (NHPs) and up to 76% mRNA knockdown.
• AL-062 (Brain-enabled Anti-α-Synuclein siRNA): AOC targeting alpha-synuclein for Parkinson's and Lewy Body Dementia. Achieved ~90% knockdown in murine and NHP models.
• GKs Enzyme (Genentech Program): A brain-enabled lysosomal enzyme therapy for Parkinson's and Lewy Body Dementia; the partner optimized the enzyme for 50x stability and potency using Elector's blood-brain barrier technology.
• Platform: Utilizes the "electro-brain carrier" (ABC) technology, a plug-and-play shuttle capable of delivering antibodies, enzymes, and siRNAs; uses a half-antibody format for superior pharmacokinetics and brain entry compared to FAB formats.

Market and Competitive Landscape:

• Alzheimer's Market: Projected to reach $70 billion; Elector views the field as crowded (16+ candidates) but believes most fail due to lack of "three features": brain entry, toxic epitope binding, and immune cell recruitment.
• Differentiation vs. Competitors: Contrasts with competitors (AbbVie, Denali, Acumen, Novartis) who utilize modified or reduced effector functions (IgG2, IgG4, LALA-PS) to mitigate safety risks; Elector argues this compromises efficacy, citing failures of drugs that achieved only 25–60% plaque reduction.
• Safety Profile: Elector's unique TFR epitope and subcutaneous delivery are designed to reduce anemia and ARIA risks associated with the transferrin receptor pathway and high-dose IV infusions, respectively.
• Intrathecal vs. Peripheral: Highlights superiority of peripheral (SC) delivery over intrathecal (IT) delivery for siRNAs (e.g., Biogen's Denorasin) by avoiding steep exposure gradients and ensuring homogeneous brain biodistribution.

Risks and Challenges:

• Efficacy Risk: Management asserts that reducing effector function (FCγR binding) to improve safety is a significant efficacy risk, as clinical success in Aβ antibodies requires >70% plaque reduction to show benefit.
• Safety Risks: While the design aims to minimize anemia, transient and reversible anemia is considered an acceptable risk if manageable; potential for infusion reactions remains a focus, though SC delivery mitigates this.
• Clinical Validation: The pGlu3 Aβ epitope represents a small fraction of total amyloid (approx. 2%), though management argues its toxicity and role in seeding plaques make it a potent target.
• Uncertain Thresholds: For alpha-synuclein knockdown, the safety threshold (max allowable reduction) is unknown, unlike Aβ where a >70% removal target is established.

Management Commentary and Tone:

• Confidence Level: High confidence and optimism regarding the "reinvention" of the company; management describes the new portfolio as "de-risked" by leveraging clinically validated epitopes and full effector functions.
• Strategic Pivot: CEO Arnon Rosenthal emphasized a fundamental shift from novel targets to validated targets with higher technical success probability, supported by the Genentech validation.
• Tone: Aggressive on efficacy goals (aiming for >90% plaque removal) while maintaining a measured stance on safety (accepting transient anemia if necessary but striving for a clean profile).

Analyst Questions and Answers:

• Anemia Mechanism: Confirmed that the drug binds the same TFR epitope on reticulocytes and the BBB but fails to co-bind FCγ receptors on immune cells, preventing reticulocyte damage while allowing effective plaque clearance.
• Trial Design: Phase 1a (6 patients, 2 placebo) and Phase 1b (15 patients, 3-4 placebo) will be placebo-controlled; data reporting for safety is expected by Q3 2027.
• Target Thresholds: Established 70% Aβ plaque reduction as the clinical minimum, with a 90% target; for tau and alpha-synuclein, targeting 50% knockdown is the primary safety/efficacy benchmark.
• Partnering Strategy: Intent is to advance the three current programs (AL-137, AL-164, AL-062) internally using Genentech funds, though future partnerships may be explored for specific indications or assets.
• Modality Choice: Preference for siRNA for targets requiring knockdown (removing a protein) versus enzymes/agonists for replacement; half-antibody format selected over FAB for superior half-life and systemic exposure.
• Safety Comparison: Belief that siRNA conjugates (AL-164) will offer a cleaner safety profile than ASO therapeutics (like Denorasin) regarding neuroinflammation and confusion.

Other Key Points:

• Manufacturing: The "plug-and-play" nature of the ABC shuttle allows for shared CMC processes across different siRNA candidates, enhancing efficiency.
• Delivery Route: A strict focus on subcutaneous (SC) administration for all new programs to enable potential home dosing, contrasting with the IV requirements of many current Aβ antibodies.
• Biomarkers: Reliance on CSF exposure (CSF levels in NHPs) as a predictive surrogate for brain exposure; use of p-tau217 and PET imaging for efficacy readouts.
• Web Questions: Clarified that the ABC shuttle is highly optimized for CNS delivery, with minimal off-target peripheral knockdown observed, and that the half-antibody format provides necessary recycling via FcRn for extended half-life.